Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells
about
Emerging roles of glycogen synthase kinase 3 in the treatment of brain tumorsGlycogen synthase kinase-3β is a crucial mediator of signal-induced RelB degradationUpregulation of RGS4 expression by IL-1beta in colonic smooth muscle is enhanced by ERK1/2 and p38 MAPK and inhibited by the PI3K/Akt/GSK3beta pathwayGSK-3 as potential target for therapeutic intervention in cancerNeuroprotection by epigallo catechin gallate against bupivacaine anesthesia induced toxicity involves modulation of PI3/Akt/PTEN signalling in N2a and SH-SY5Y cellsA New alpha5beta1 integrin-dependent survival pathway through GSK3beta activation in leukemic cellsPhosphorylated IκBα predicts poor prognosis in activated B-cell lymphoma and its inhibition with thymoquinone induces apoptosis via ROS releaseGSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animalsPrimers on molecular pathways. The glycogen synthase kinase-3betaGlycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapyPro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region.Glycogen synthase kinase 3 regulates PAX3-FKHR-mediated cell proliferation in human alveolar rhabdomyosarcoma cells.Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell deathClinicopathological and biological significance of aberrant activation of glycogen synthase kinase-3 in ovarian cancerCombination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models.Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia.Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells.Glycogen Synthase Kinase 3β Inhibitor (2'Z,3'E)-6-Bromo-indirubin- 3'-Oxime Enhances Drug Resistance to 5-Fluorouracil Chemotherapy in Colon Cancer Cells.Glycogen synthase kinase 3 protein kinase activity is frequently elevated in human non-small cell lung carcinoma and supports tumour cell proliferation.CG0009, a novel glycogen synthase kinase 3 inhibitor, induces cell death through cyclin D1 depletion in breast cancer cells.Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}.Enhancing effect of β-elemene emulsion on chemotherapy with harringtonine, aclacinomycin, and Ara-c in treatment of refractory/relapsed acute myeloid leukemia.GSK3β overexpression indicates poor prognosis and its inhibition reduces cell proliferation and survival of non-small cell lung cancer cellsDisruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acid.Functions of GSK-3 Signaling in Development of the Nervous System.Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression.GSK-3β regulates tumor growth and angiogenesis in human glioma cellsRepression of GSK3 restores NK cell cytotoxicity in AML patients.Glycogen synthase kinase 3beta-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles.Nuclear factor-κB modulates osteogenesis of periodontal ligament stem cells through competition with β-catenin signaling in inflammatory microenvironments.A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factorsGlycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy.Nuclear GSK3β promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22.Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.Targeting the Wnt signaling pathway to augment bone formation.Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma.Alternative Interventions to Prevent Oxidative Damage following Ischemia/ReperfusionInhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer.
P2860
Q21129333-8C9F52E1-F064-4B4F-AE48-4A182168C3AFQ24336114-A5020EF1-B3AC-4177-8E6C-3D03C6F22D7DQ24649749-B9DE37FB-EAF6-455D-9571-726A8E19063FQ27013811-E7C8870B-B986-43DF-ACDD-905F031EB1D5Q28394702-7F44E294-3631-4B13-ACAB-C24D7AED22A9Q28473374-1EEE3B6E-F6EA-4B61-855B-787E999E1E28Q28489100-BECE188A-6C77-4C72-96BF-403248CA4EA3Q30619452-E1E9841C-412A-4A19-B2CB-C2C88957FC21Q33301293-82ABF907-DCD0-4ACC-871B-90696D821939Q33437264-860BFF4F-E054-43A5-96F8-2D652C238F8BQ33579784-6DE8A252-F470-4968-95B1-66DF16E1843BQ33615694-4FF7B7DE-A768-4467-8466-2628AE5104EAQ33710200-B483DA11-1447-4040-AD05-C2457FF404DDQ33831250-EE046D94-777A-4B84-8D3D-FEEF2CBEE972Q33869702-266AAFF6-0F8F-451F-A628-61601C05F2DEQ34081881-ADB60E48-AEDC-44AE-95E1-1798590E94CDQ34103963-821852BF-7D75-42D5-8FB9-7C4B71FEB0F3Q34156754-E136DE3E-D525-478D-8F49-1C0555524DBFQ34419599-642C6F15-D37A-4B47-8498-4CFBB4DFEDE5Q34566456-AE0E9EC2-B09E-46D8-9099-2A0325E1D4AFQ34654039-1B6793A7-56B4-4404-BD78-67144F09DB7CQ34658396-5B5D9C58-D24D-4466-B1C9-146C98661C4EQ34808205-58A037F7-60E4-411E-A5C2-C21C418F9570Q35060955-53AFF32B-3A17-43CF-9488-F90B89FEFF17Q35117724-2396DEBD-0B57-49D8-AC24-F59D4B03E0C2Q35309369-C871D6CB-2886-42A2-94F9-FFE417B494BBQ35564819-00D33E44-E680-499D-A4BE-606FEAE7178DQ36019650-1CB5BEE3-AA18-48EF-87DF-6753EA652700Q36544729-33B51654-CC83-456E-B326-6927BF6C90E3Q36768725-2F01567D-57B6-487D-8EE3-C4D124A5362FQ36994922-2C759019-4E17-4CE1-A329-9DD59AE79D53Q37073554-D143D8AE-3F78-411C-A91F-1487DEE96BE6Q37105231-E3EA31DF-72FC-4A17-87F3-7FDE4ED6ADA9Q37163149-E8B68260-78C7-4B9E-A8ED-8BBAD3F62E67Q37262177-86E3DA05-4FB6-47D3-9DA3-023395195B65Q37460101-7EF22D42-8ED6-476A-B3E7-DEE1D0D6703CQ37479050-10A3CA63-62B2-43C0-B867-643C2C8F9BC0Q37481890-7AA2FF36-2A01-439F-9511-DCF1062AB74FQ37578724-81610341-5FC1-4305-A8D7-12404FD67D11Q37640802-1E448F37-5923-429B-9EFE-AD59218F58CD
P2860
Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappaB target genes and induction of apoptosis in chronic lymphocytic leukemia B cells
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Inhibition of glycogen synthas ...... c lymphocytic leukemia B cells
@ast
Inhibition of glycogen synthas ...... c lymphocytic leukemia B cells
@en
type
label
Inhibition of glycogen synthas ...... c lymphocytic leukemia B cells
@ast
Inhibition of glycogen synthas ...... c lymphocytic leukemia B cells
@en
prefLabel
Inhibition of glycogen synthas ...... c lymphocytic leukemia B cells
@ast
Inhibition of glycogen synthas ...... c lymphocytic leukemia B cells
@en
P2093
P2860
P921
P1433
P1476
Inhibition of glycogen synthas ...... c lymphocytic leukemia B cells
@en
P2093
Andrei V Ougolkov
Daniel D Billadeau
Martin E Fernandez-Zapico
Nancy D Bone
Neil E Kay
P2860
P304
P356
10.1182/BLOOD-2006-12-060947
P407
P577
2007-04-26T00:00:00Z